CIRSE Emprint Microwave Ablation Registry

Prior treatment

• Patients receiving simultaneous bowel surgery and microwave ablation
• Patients receiving simultaneous IRE, RFA, SBRT, Cryoablation, HIFU or other local treatment than resection

Other illness

• Ongoing infection (viral/bacterial)
• Active cancers other than CRC
• Non-resected primary colon cancer
• Advanced liver disease or evidence of liver insufficiency

Other

• Life expectancy less than 6 months (palliative treatment)
• Extrahepatic metastases with the exception of a maximum of 5 lung nodules
• Pregnancy
• Patients with liver metastases that cannot be completely and safely treated

• 18 years or older
• Proven colorectal liver metastases either histologically proven or diagnosed by imaging in a patient with known colorectal cancer
• Treated with the Emprint or Emprint HP Microwave ablation system
• Patient referred to MWA by a multidisciplinary tumour board
• Signed informed consent form
• Intention to completely treat (ablation, resection, SBRT) all visible disease within 8 weeks
• Maximum number of 9 total liver lesions
• All liver lesions must be local treatment-naive
• Maximum diameter of the largest liver lesion treated with MWA must not exceed 3cm
• Maximum diameter of lesions treated surgically may exceed this limitation
• Maximum number of 5 lung nodules eligible to be treated
• Patients may receive simultaneous liver resection and microwave ablation
• Patients may have received previous systemic therapy
• Patients must not have received surgical resection or thermal ablation for other liver lesions in the last 3 months before inclusion
• Patients treated with a liver-first approach may be included if treatment of the primary tumour is planned
• If applicable: complete response of treated rectal tumour proven by imaging